ArticleInternational urology and nephrology2025
Analysis of antibiotic resistance and risk factors of extended-spectrum beta-lactamases-producing Escherichia coli in hospitalized children with community-acquired urinary tract infections.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multidrug-resistant uropathogens in pediatric urinary tract infections: a multicenter retrospective trend analysis (2020-2024).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Bacterial isolates and antibiotic resistance in critically ill sepsis patients at a tertiary hospital in Ethiopia.BMC infectious diseases · 2025Article
- Analysis of pathogen distribution and serum procalcitonin level alterations in patients with type 2 diabetes mellitus complicated by urinary tract infections.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe incidence of extended-spectrum beta-lactamases (ESBLs)-producing Escherichia coli (E. coli) infections is rising. This study investigates the antibiotic resistance profiles and risk factors associated with ESBL-producing E. coli in urinary tract infections (UTIs) among hospitalized children, providing a basis for rational clinical management.
methodsWe analyzed the clinical data of 140 children diagnosed with UTIs caused by E. coli at Anhui Provincial Children's Hospital from July 2021 and June 2024 in this retrospective study.
resultsAmong the 140 E. coli strains isolated, the male-to-female ratio was 1.75:1, with a median age of 7 months. Seventy-five strains (53.6%) were identified as ESBL producers. Non-ESBL-producing strains exhibited the highest resistance to ampicillin (60%) and lower resistance rates to cephalosporins and monobactams. Resistance rates for ampicillin-sulbactam, piperacillin-tazobactam, and cefoperazone-sulbactam were 29.2%, 6.2%, and 6.2%, respectively. No resistance to nitrofurantoin was observed, and only two strains were resistant to carbapenems. ESBL-producing strains demonstrated significantly higher resistance rates to most clinically relevant antimicrobials compared to non-producing strains. Among cephalosporins, resistance rates exceeded 90% for cefazolin, cefuroxime, and ceftriaxone, followed by cefepime (65.3%) and ceftazidime (29.3%). Notably, resistance to ampicillin-sulbactam was 50.7%, with greater sensitivity observed for cefoperazone-sulbactam and piperacillin-tazobactam. Resistance to cefotetan and nitrofurantoin remained low, and no carbapenem-resistant ESBL-producing strains were identified. Multifactorial logistic regression analysis indicated that abnormal urinary tract structure and a history of antibiotic treatment within the past 3 months were independent risk factors for UTIs caused by ESBL-producing E. coli (OR = 2.323, 95% CI = 1.052-5.129, P = 0.037 and OR = 3.378, 95% CI = 1.116-10.224, P = 0.031, respectively).
conclusionsESBL-producing E. coli infections in pediatric UTIs are very common in our hospital, with high resistance rates to many used antibiotics. Awareness of the risk factors-namely, abnormal urinary tract structure and recent antibiotic treatment-is essential for effective management. Empirical treatment should involve a rational selection of antimicrobials based on local bacterial resistance patterns.
Indexed as
Identifiers
39948286What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.